Selina Tsim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8359828/publications.pdf

Version: 2024-02-01

18	796	11	18
papers	citations	h-index	g-index
18	18	18	972
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. Thorax, 2022, , thoraxjnl-2021-217808.	2.7	6
2	Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial). BMJ Open Respiratory Research, 2021, 8, e000846.	1.2	4
3	Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. Journal of Thoracic Oncology, 2021, 16, 1705-1717.	0.5	10
4	Intrapleural Fibrinolytics and Deoxyribonuclease for Treatment of Indwelling Pleural Catheter-Related Pleural Infection: A Multi-Center Observational Study. Respiration, 2021, 100, 452-460.	1.2	9
5	Interâ€observer variation in image interpretation and the prognostic importance of nonâ€expansile lung in malignant pleural effusion. Respirology, 2020, 25, 298-304.	1.3	15
6	A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 2020, 150, 12-20.	0.9	11
7	Chest drain aerosol generation in COVID-19 and emission reduction using a simple anti-viral filter. BMJ Open Respiratory Research, 2020, 7, e000710.	1.2	12
8	Pre-EDIT. Chest, 2019, 156, 1204-1213.	0.4	22
9	Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy – Data supporting â€~Direct to LAT' in selected groups. Lung Cancer, 2019, 133, 123-129.	0.9	20
10	Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors. BMJ Open Respiratory Research, 2018, 5, e000240.	1.2	132
11	BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respiratory Research, 2018, 5, e000266.	1.2	35
12	British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax, 2018, 73, i1-i30.	2.7	157
13	Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy. Lung Cancer, 2018, 118, 48-56.	0.9	26
14	Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respiratory Research, 2018, 5, e000293.	1.2	5
15	The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 2017, 103, 38-43.	0.9	40
16	Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. European Respiratory Review, 2016, 25, 472-486.	3.0	225
17	Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 2016, 101, 48-58.	0.9	38
18	Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. BMJ Open, 2016, 6, e013324.	0.8	29